nDatalyze announces updates on Private Placement
Calgary, Alberta – March 21, 2022
For Immediate Release – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE: NDAT)(OTC: NDATF)
announces the Corporation has issued a total of 1,534,000 units (“Units”), for proceeds of $383,500, under its previously announced private placement (“Offering”). Each Unit consisted of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire one common share AT $0.35 for 12 months from the date of issuance, subject to the accelerated expiry provision described in the Corporation’s February 4, 2022 news release.
The Corporation expects to close additional tranches of the Offering shortly. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation in Canada.
The proceeds from the Offering will be used for general working capital. The Corporation may pay finders fees and finder warrants to eligible finders.
About nDatalyze Corp.:
nDatalyze Corp. generates technology-based, health-related solutions. The YMI division is developing a machine-learning based, online consumer mental health application and the MLdelic division is focusing on applying machine-learning to assist in the prediction of potential benefits associated with the use of entheogenic compounds within the mental health sector. Both YMI and MLdelic are based on the Corporation’s proprietary Reference Database consisting of >1200 biometric records complete with “same-time-of-day” EEG data. With installations worldwide, its Medxtractor division manufactures and sells small-scale bio-extractors that are used to extract compounds from a variety of botanical biomasses. While the Medxtractor division is currently generating cash flow, both YMI and MLdelic are in development and accordingly the Corporation cannot accurately predict if or when these applications will become cash flow generators.
FOR FURTHER INFORMATION, PLEASE CONTACT:
James Durward, President and CEO
Telephone: (403) 689-3901
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.